Retinoblastoma Morphology after Local Chemotherapy

Purpose. Determine the nature of tumor regression and possible complications associated with the retinotoxic effect of melphalan and carboplatin with local chemotherapy.

Methods. A histological analysis of 19 enucleated eyes from 19 patients with retinoblastoma was performed after combined organ-preserving treatment, including systemic chemotherapy and local chemotherapy in various doses. The enucleated eyes were fixed in 10 % formalin and processed routinely for histological examination.

Results. Significant changes in the tumor tissue such as tumor regression associated with the destruction of the tumor tissue and its replacement with fibrous tissue, glia proliferation, and the formation of petrificates were revealed. Complete regression of the tumor was detected in 3 out of 19 eyes, partial in 13 eyes. There were no signs of regression in 3 eyes. Tumor invasion into the choroid was found in 5 cases, into the anterior sector — in 3 cases, into the optic nerve — in 3 cases. The retrobulbar tumor was presented in 1 case. Retinotoxic complications revealed. Hemorrhagic changes associated with focal necrosis of the central retinal vessels (n = 4), destructive changes in retinal pigment epithelium (RPE; n = 10) associated with the accumulation of melphalan in RPE leading to atrophic processes in the retina. Complications in the form of secondary glaucoma, severe fibrosis and retinal detachment, despite the complete resorption of the tumor, led not only to loss of vision, but also hindered visualization of the fundus and substantiated the need for enucleation in 3 cases. In other cases, enucleation was performed due to continued tumor growth (n = 16) or progression during treatment (n = 3).

Conclusions. Retinoblastoma can be controlled with local chemotherapy. However, clinical and morphological examinations of enucleated eyes revealed and confirmed, along with tumor resorption, intraocular complications as a result of the toxic effect of the drugs and the presence of active tumor tissue to varying degrees of therapeutic pathomorphism, which can be explained by the resistance of RB to these drugs. Thus, a further search is needed for drugs that destroy the tumor and minimize the retinotoxic effect.

1. Kaneko A., Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–607.

2. Munier F.L., Gaillard M.C., Balmer A., Soliman S., Podilsky G., Moulin A.P., BeckPopovic M. Intravitreal chemotherapy for vitreous disease in retinoblastoma revisited: from prohibition to conditional indications. Br J Ophthalmol. 2012;96(8):1078–1083. DOI: 10.1136/bjophthalmol-2011-301450

3. Ushakova T.L., Trofimov I.A., Gorovtsova O.V., Yarovoi A.A., Saakyan S.V., Letyagin I.A., Matinyan N.V., Kukushkin A.V., Martynov L.A., Pogrebnyakov I.V., Ivanova O.A., Serov Yu.A., Yarovaya V.A., Glekov I.V., Virshke E.R., Dolgushin B.I., Polyakov V.G. A New Era of Organ-Preserving Treatment in Pediatric Intraocular Retinoblastoma in Russia: A Multicenter Cohort Study. Oncopediatrics = Onkopediatriya. 2018;5(1):51–69 (In Russ.). DOI: 10.15690/onco.v5i1.1866

4. Shields C.L., Lally S.E., Leahey A.M. Targeted retinoblastoma management: when to use intravenous, intra-arterial, periocular, and intravitreal chemotherapy. Curr. Opin. Ophthalmol. 2014;25(5):374–385. DOI: 10.1097/ICU.0000000000000091

5. Shields C.L., Manjandavida F.P., Lally S.E. Intra-arterial chemotherapy for retinoblastoma in 70 eyes: outcomes based on the international classification of retinoblastoma. Ophthalmology. 2014;121(7):1453–1460. DOI: 10.1016/j.ophtha.2014.01.026

6. Dolgushin B.I., Ushakova T.L., Pogrebnyakov I.V., Trofimov I.A., Kukushkin A.V., Virshke E.R., Gorovtsova O.V., Serov Yu.A., Yarovoi A.A., Saakyan S.V., Polyakov V.G. The role of selective intraaterial and intravitreal chemotherapy in organ-preserving treatment of the children with an intraocular retinoblastoma. Trans-Baikal Medical Bulletin = Zabaikal’skiy meditsinskiy vestnik. 2018;1:7–24 (In Russ.).

7. Linn Murphree A. Intraocular Retinoblastoma: the Case for a New Group Classification. Ophthalmology Clinics of North America. 2005;18(1):41–53. DOI: 10.1016/j.ohc.2004.11.003

8. Ericson L.A., Rosengren B.H. Present therapeutic resources in retinoblastoma. Acta Ophthalmol (Copenh). 1961;39:569–576. DOI: 10.1111/j.1755-3768.1961.tb00269.x

9. Kaneko A., Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding. Jpn J Clin Oncol. 2003;33(12):601–607.

10. Kivelä T., Eskelin S., Paloheimo M. Intravitreal methotrexate for retinoblastoma. Ophthalmology. 2011;118(8):1689–1689.e1–6. DOI: 10.1016/j.ophtha.2011.02.005

11. Francis J.H., Schaiquevich P., Buitrago E., Del Sole M.J., Zapata G., Croxatto J.O., Marr B.P., Brodie S.E., Berra A., Chantada G.L., Abramson D.H. Local and systemic toxicity of intravitreal melphalan for vitreous seeding in retinoblastoma: a preclinical and clinical study. Ophthalmology. 2014;121:1810–1817. DOI: 10.1016/j.ophtha.2014.03.028

12. Munier F.L. Classification and management of seeds in retinoblastoma. Ellsworth Lecture Ghent August 24th 2013. Ophthalmic Genet. 2014;35:193–207. DOI: 10.3109/13816810.2014.973045

13. Ghassemi F., Shields C.L. Intravitreal melphalan for refractory or recurrent vitreous seeding from retinoblastoma. Arch Ophthalmol. 2012;130(10):1268–1271. DOI: 10.1001/archophthalmol.2012.1983

14. Ghassemi F., Amoli F.A. Pathological findings in enucleated eyes after intravitreal melphalan injection. Int Ophthalmol. 2014;34:533–540. DOI: 10.1007/s10792-0139851-2

15. Smith S.J., Smith B.D., Mohney B.G. Ocular side effects following intravitreal injection therapy for retinoblastoma: a systematic review. Br J Ophthalmol. 2014;98(3):292–297. DOI: 10.1136/bjophthalmol-2013-303885

16. Aziz H.A., Kim J.W., Munier F.L., Berry J.L. Acute Hemorrhagic Retinopathy following Intravitreal Melphalan Injection for Retinoblastoma: A Report of Two Cases and Technical Modifications to Enhance the Prevention of Retinal Toxicity. Ocular Oncology and Pathology. 2016;3(1):34–40. DOI: 10.1159/000448718

17. Khoroshilova-Maslova I.P., Leparskaya N.L. Retinal changes after intravitreal injections of various concentrations of antiproliferative medication Melphalan: an experimental and morphological study. Russian Ophthalmological Journal = Rossiiskiy oftal’mologicheskiy zhurnal. 2018;11(1):36–40 (In Russ.). DOI: 10.21516/20720076-2018-11-1-36-40

18. Saakyan S.V., Myakoshina E.B., Polyakov V.G., Ushakova T.L., Ismailova D.M. Maculopathy and chorioretinopathy in children with retinoblastoma during chemotherapy: clinical and morphometric studies. Russian pediatric ophthalmology = Rossiiskaya pediatricheskaya oftal’mologiya. 2018;13(4):167–175 (In Russ.).

19. Inomata M., Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay. Jpn J Cancer Res. 1987;78(8):858–868.

20. Eagle R.C., Shields C.L., Bianciotto C., Jabbour P., Shields J.A. Histopathologic Ob‑ servations After Intra-arterial Chemotherapy for Retinoblastoma. Arch Ophthalmol. 2011;129(11):1416–1421. DOI: 10.1001/archophthalmol.2011.223

21. Biewald E.M., Bornfeld N., Metz K.A. Histopathology of retinoblastoma eyes enucleated after intra-arterial chemotherapy. Br J Ophthalmol 2020 Aug;104(8):1171–1175.

22. Vajzovic L.M., Murray T.G., Aziz-Sultan M.A. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma. Arch Ophthalmol. 2010;128(12):1619–1623. DOI: 10.1001/archophthalmol.2010.296

23. Abramson D.H., Dunkel I.J., Brodie S.E., Kim J.W., Gobin Y.P. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results. Ophthalmology. 2008;115(8):1398–1404. DOI: 10.1016/j.ophtha.2007.12.014

24. Daniels, A.B., Froehler, M.T., Nunnally A.H. Rabbit Model of Intra-Arterial Chemotherapy Toxicity Demonstrates Retinopathy and Vasculopathy Related to Drug and Dose, Not Procedure or Approach. Investigative Opthalmology & Visual Science. 2019;60(4):954–964. DOI: 10.1167/iovs.18-25346

25. Zueva M.V., Tsapenko I.V., Saakyan S.V., Panteleeva O.G., Zharua A.A., Orlovskaya L.S. Evoked potentials of the retina and visual cortex in children with advanced and resistant retinoblastoma after neoadjuvant chemotherapy and superselective intra-arterial chemotherapy. Annales of Ophthalmology = Vestnik oftal’mologii. 2014;5:22–29 (In Russ.).

26. Saakyan S.V., Tsygankov A.Y., Moiseeva N.I., Karamysheva A.F., Zhil’tsova M.G., Tadevosyan S.S. Retinoblastoma Cell Culturing and Evaluation of Their Drug Resistance. Experimental Biology and Medicine = Byulleten’ ehksperimental’noy biologii i mediciny. 2018;165(1):148–153 (In Russ.). DOI: 10.1007/s10517-018-4117-7

27. Saakyan S.V., Tsygankov A.Yu., Khoroshilova-Maslova I.P., Moiseeva N.I., Karamysheva A.F., Zhil’tsova M.G., Amiryan A.G., Tadevosyan S.S. Development of intraocular retinoblastoma in vivo model. Experimental Biology and Medicine = Byulleten’ ehksperimental’noy biologii i mediciny. 2020;169(3):387–390 (In Russ.).

28. Ushakova T.L., Dolgopolov I.S., Sokolova Z.A., Chkadua G.Z., Titov N.S., Bukreev Y.M., Serov Y.A., Gorovtsova O.V., Buletov D.A., Kozlov N.A., Polyakov V.G. Experimental immunotherapy model of retinoblastoma. Russian Journal of Biotherapy = Rossiiskiy bioterapevticheskiy zhurnal. 2019;18(4):57–64 (In Russ.). DOI: 10.17650/1726-9784-201918-4-57-64